drugset
Drugs / Dendritic Cell/Tumor Fusion Vaccine
last change Oct 2014 re-read 9 days ago

Dendritic Cell/Tumor Fusion Vaccine

Vaccine

Developed for
breast cancer
Investigated by
Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Dana-Farber Cancer Institute · Harvard Medical School (HMS and HSDM) · National Cancer Institute (NCI) · United States Department of Defense

Trials 1

today NCT00622401 · Ph 1/2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00622401 Dec 2009 → Oct 2014 breast cancer Beth Israel Deaconess Medical Center Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Dendritic Cell/Tumor Fusion Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00622401 ↗
Modality Vaccine “investigational Dendritic Cell/Tumor Fusion vaccine” NCT00622401 ↗
Route Subcutaneous “injection of tumor cells fused with dendritic cells under the skin every 3 weeks” NCT00622401 ↗